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Abstract:  Azaspiracids (AZA) are polyether marine toxins that accumulate in various 
shellfish species and have been associated with severe gastrointestinal human intoxications 
since 1995. This toxin class has since been reported from several countries, including 
Morocco and much of western Europe. A regulatory limit of 160 µg AZA/kg whole 
shellfish flesh was established by the EU in order to protect human health; however, in 
some cases, AZA concentrations far exceed the action level. Herein we discuss recent 
advances on the chemistry of various AZA analogs, review the ecology of AZAs, including 
the putative progenitor algal species, collectively interpret the in vitro and in vivo data on 
the toxicology of AZAs relating to human health issues, and outline the European 
legislature associated with AZAs.  
Keywords: azaspiracid (AZA), AZP, shellfish poisoning. 
 
Abbreviations: ARfD, acute reference dose; ASP, amnesic shellfish poisoning; ASTOX, 
Azaspiracid Standards and Toxicology; AZA, azaspiracid; AZP, azaspiracid shellfish poisoning; 
BTX, brevetoxins; cAMP, cyclic adenosine monophosphate; CRL, community reference 
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laboratory; CRM, certified reference material; DA, domoic acid; DSP, diarrhetic shellfish 
poisoning; DTX, dinophysistoxin; ECVAM, European Centre for the Validation of Alternative 
Methods; ELISA, enzyme-linked immunosorbent assay; EU-DG Sanco, EU Commission for 
Health and Consumer Protection; FSA, Food Standards Agency; FSAI, Food Safety Authority of 
Ireland; G6PH, glucose-6-phosphate dehydrogenase; GI, gastrointestinal; HP, hepatopancreas; 
HPLC, high performance liquid chromatography; IBD, inflammatory bowel disease; IP, 
intraperitoneal; IRMM, Institute for Reference Materials and Measurement; KT, Killary-toxin; 
LC-MS, liquid chromatograph-mass spectrometry; LD50, lethal dose, 50%; LDH, lactose 
dehydrogenase; LDLR, low density lipoprotein receptor; LOAEL, lowest observable adverse 
effect level; LOQ, limit of quantification; MAPK, mitogen activated protein kinase; MTS, 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium;  MTT, 3-(4, 
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide; NMR, nuclear magnet resonance; 
NOAEL, no observable adverse effect level; NRC-Canada, National Research Council Canada; 
NRL, National Reference Laboratory; OA, okadaic acid; PKC, protein kinase C; PP, protein 
phosphatase; PSP, paralytic shellfish poisoning; PTX, pectenotoxin; QUASIMEME, Quality 
Assurance in Marine Environmental Matrices in Europe; SEC, size exclusion chromatography; 
SPX, spirolides; TEER, transepithelial electrical resistance; YTX, yessotoxins 
 
1. Introduction 
In 1995, there was an outbreak of human illness in the Netherlands that was associated with 
ingestion of contaminated shellfish originating from Killary Harbour, Ireland. Although the symptoms 
were typical of diarrhetic shellfish poisoning (DSP) toxins such as okadaic acid (OA) and 
dinophysistoxins (DTX), the levels of DSP toxins in these shellfish were well below the regulatory 
level. Over the next two years it was established that these shellfish were contaminated with a unique 
marine toxin, originally named “Killary-toxin” or KT-3 
1. Shortly thereafter, the toxin was renamed to 
azaspiracid (AZA) to more appropriately reflect the chemical structure of this compound 
1, 2. Since the 
original azaspiracid poisoning (AZP) event, four additional AZP events have occurred due to 
contaminated Irish mussels (Table 1).  
Over the last decade, various analogs of AZA have been identified in shellfish of many coastal 
regions of western Europe, as well as NW Africa 
4 and eastern Canada (M. Quilliam, pers. comm.). 
Although extensive study of this toxin class has been constrained by limited availability of purified 
material, certified reference standards of naturally produced AZA1 are now commercially available. 
Limits on toxin supply may be further alleviated by the recent in vitro total synthesis of AZA1 
5. The 
stage is now set to move forward rapidly in improving our overall understanding of AZAs. While 
certain aspects of these toxins and their pharmacological effects have been summarized previously 
6, 7, 
we feel the timing is appropriate to critically review the advances in AZA research over the last 12 
years emphasizing the chemistry, ecology, toxicology and human health impacts of AZAs, and 
identifying critical areas for future research.  
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Table 1. Reported cases of azaspiracid poisoning (AZP) 1995-2007 
3. 
                 
Location of 
AZP 
Date 
Implicated food 
source 
Amount 
consumed 
Area of 
production 
Number of 
illnesses recorded 
Netherlands  
November 
1995 
Mussels (Mytilus 
edulis) 
Not 
recorded 
Killary 
Harbour, 
Ireland 
8 
Ireland  
September / 
October 
1997 
Mussels (M. edulis) 
“As few as 
10-12 
mussels” 
Arranmore 
Island, Ireland  
Estimated 20-24 (8 
seen by a doctor) 
Italy  
September 
1998 
Mussels (M. edulis) 
Not 
recorded 
Clew Bay, 
Ireland  
10 
France  
September 
1998 
Scallops (Pecten 
maximus) 
Not 
recorded 
Bantry Bay, 
Ireland  
Estimated 20-30 
United 
Kingdom  
August 
2000 
Frozen mussels (M. 
edulis) 
Not 
recorded 
Bantry Bay, 
Ireland  
12-16 
 
2. Chemistry of AZAs 
2.1. Structure and analogs of AZA 
The structure of AZA1 (MW 841.5) was first reported in 1998 after successful isolation from Irish 
blue mussel (Mytilus edulis) material 
2. A cyclic amine (or aza group), a unique tri-spiro-assembly and 
a carboxylic acid group gave rise to the name AZA-SPIR-ACID.  The original structure reported in 
1998 was found to contain an error, after attempts of synthesis were carried out in 2003 
8, 9. The 
synthesised compound was found to have a different chromatographic behaviour and discrepancies in 
its nuclear magnetic resonance (NMR) spectrum compared to the compound isolated from natural 
sources. Further extensive study of the NMR spectra and more analysis resulted in structure revision in 
2004 (Fig. 1) 
10, 11. A detailed review of the synthetic approach and structure revision has recently been 
published 
12.  
Shortly after structure elucidation of AZA1, four additional analogs of the toxin were discovered 
and, after their preparative isolation, their structure was determined using MS and NMR techniques 
13, 
14. Three of these isolated analogs differ only in the number of methyl groups. Compared to AZA1, 
AZA3 is lacking the C22 positioned methyl moiety and AZA2 possesses an additional CH3 at position 
C8 (Fig. 1).  The other two analogs of the toxin (AZA4 and AZA5) proved to be hydroxyl analogs of 
AZA3, showing the presence of an additional OH group at either C3 (AZA4) or at C23 (AZA5). 
So far, only AZAs 1 through 5 have been preparatively isolated, with their structure verified using 
NMR techniques. Structure elucidation of other analogs has been solely based on the analysis of 
fragmentation patterns of the respective MS/MS spectra 
15-17.  AZAs produce characteristic product ion 
spectra with four significant fragmentation groups (Figure 2) 
15-18. Analysis of the different fragments 
has led to the identification of up to 27 different naturally occurring analogs of AZA1 as well as 
methyl esters of AZAs, which have been identified to be storage artefacts (Table 2) 
17. Mar. Drugs. 2008, 6  42
 
Figure 1.  Structure of AZA1 (left) and the originally proposed structure (right).   
Differences between the structures are observed by the stereo-chemical orientation of rings 
C/D including C20, and rings F/G/H/I.   
 
8
O O
O
15
O
O 33
34
NH
O
O
27
23
22 21
O
20
H
H
H
H
H
H
CH3
3
2
1
H
O
OH
OH
H
HO
A
B
C D
E
F
G
H
I
8
O O
O
15
O
O 33
34
NH
O
O
27
23
22
21
O
20
H
H
H
H
H
H
CH3
3
2
1
H
O
OH
OH
H
HO
A
B
C D
E
F
G
H
I
 
 
AZA6, was reported to be a positional isomer of AZA1 lacking the C22 methyl group but 
possessing the methyl group at C8 
15, 16. In addition, hydroxy-analogs of AZA1 and AZA2 were 
reported 
16. Very recently 12 more analogs of AZA have been reported 
17. Among these analogs were 
dihydroxy AZAs for AZA1-3 and AZA6, as well as carboxy and carboxy-hydroxy analogs.  In-depth 
analysis of the fragmentation pathways has shown that C23 hydroxylated AZAs produce a fragment 
ion at m/z 408 undergoing two water losses and resulting in a fragment ion at m/z 372.  Those fragment 
ions are not observed with AZA analogs that do not possess an additional OH at C23.  This special 
fragmentation pathway has aided in determining the structure of some analogs, revealing a consistent 
substitution of the proton at this position with a hydroxyl group. 
For a number of lipophilic shellfish toxins like pectenotoxins (PTXs), OA, DTXs, brevetoxins 
(BTXs), and also spirolides (SPXs), fatty acid ester derivatives have been reported in shellfish tissue 
19-22.  Although no such esters have been identified for AZA, a variety of hydroxy-, dihydroxy- and 
carboxy-analogs have been discovered for AZAs (Table 2).  This is not unlike analogs of YTX, where 
more than 80 different analogs of YTX have been reported to date 
23-26 with no evidence for YTX fatty 
acid esters.  As such, the formation of AZA toxin analogs in shellfish is similar to that of YTX with the 
possibility that more AZA analogs will be discovered in the future.  Mar. Drugs. 2008, 6  43
 
Figure 2. Product ion spectrum of AZA1 with significant fragmentation pattern. 
 
824
806
788
770
672
658
640
362
462
m/z
300 400 500 600 700 800 900
%
20
40
60
80
100
842
824
806
788
770
672
654
636
462
444
362
344
 
 
2.2. Physico-chemical properties and stability of AZAs 
 
AZA1 was initially reported as a colourless, odourless, amorphous solid with the chemical formula 
C47H71NO12 and a molecular weight of 841.5  g/mol 
1, 2. Other studies reported the toxin to be a 
colourless oil 
5, 10.  No UV absorption maxima were found above 210  nm wavelength and the 
refractive index of AZA1 was determined to be [α]
20-21 (c 0.10, MeOH).  At physiological pH, AZA1 
exists as a zwitterion (i.e., contains both a positive and negative charge but is electrically neutral), 
which would confer detergent-like properties to this molecule 
7.  This overall neutral but potentially 
ionic character may result in enhanced possibilities for interaction of AZA with its biological target.    
Little information is available about the stability of AZAs. During the production of a tissue 
reference material, certain techniques were tested to stabilise the tissue material for long-term storage. 
During a heat treatment study the toxins were observed to degrade when heated over 90  °C 
27; 
however, the use of gamma irradiation, which is often used to stabilise tissue reference materials, had 
little effect on AZA analog stability when contained in mussel matrix. Interestingly, the toxins were 
observed to undergo rapid degradation when irradiated as a pure compound in solution 
28.  AZAs 
stored in methanol were shown to slowly form methyl esters of the toxin 
17. These esters were only 
observed in methanol extracts stored at room temperature or higher for prolonged periods (i.e., several 
months).  A similar phenomenon has been shown to also occur with brevetoxin-B (PbTx-2 adduct m/z 
927) 
29. 
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Several studies have also reported the detection of AZA-like isomers that show similar or identical 
MS/MS spectra, but different chromatographic behaviour (Table 2) 
17, 30. These isomers have not been 
properly characterized yet as it is first necessary to have purified material with corresponding NMR 
spectra in order to prove stereo-chemical differences between the compounds.  
 
Table 2. Overview of all reported AZA analogs. 
 
Abbrev. 
Original  
analog 
Substituent Name Ref. 
AZA1     Azaspiracid  2 
AZA2     8-methyl-azaspiracid  14 
AZA3     22-desmethyl-azaspiracid  14 
AZA4 AZA3  OH  22-desmethyl-3-hydroxy-azaspiracid  13 
AZA5 AZA3  OH  22-desmethyl-23-hydroxy-azaspiracid  13 
AZA6     22-desmethyl-8-methyl-azaspiracid  15,  16
AZA7 AZA1  OH  3-hydroxy-azaspiracid  16 
AZA8 AZA1  OH  23-hydroxy-azaspiracid  16 
AZA9 AZA6  OH  22-desmethyl-3-hydroxy-8-methyl-azaspiracid  16 
AZA10 AZA6  OH  22-desmethyl-23-hydroxy-8-methyl-azaspiracid  16 
AZA11 AZA2  OH  3-hydroxy-8-methyl-azaspiracid  16 
AZA12 AZA2  OH  23-hydroxy-8-methyl-azaspiracid  16,  17
AZA13 AZA3  2  OH  22-desmethyl-3,23-dihydroxy-azaspiracid  17 
AZA14 AZA1  2  OH  3,23-dihydroxy-azaspiracid  17 
AZA15 AZA6  2  OH  22-desmethyl-3,23-dihydroxy-8-methyl-azaspiracid 17 
AZA16 AZA2  2  OH  3,23-dihydroxy-8-methyl-azaspiracid  17 
AZA17 AZA3  COOH carboxy-22-desmethyl-azaspiracid  15,  17
AZA18 AZA1  COOH carboxy-azaspiracid  17 
AZA19 AZA6  COOH carboxy-22-desmethyl-8-methyl-azaspiracid  17 
AZA20 AZA2  COOH carboxy-8-methyl-azaspiracid  17 
AZA21 AZA3  COOH  +  OH  carboxy-22-desmethyl-3-hydroxy-azaspiracid  17 
AZA22 AZA1  COOH  +  OH  carboxy-3-hydroxy-azaspiracid  17 
AZA23 AZA6  COOH  +  OH  carboxy-22-desmethyl-3-hydroxy-8-methyl-azaspiracid 17 
AZA24 AZA2  COOH  +  OH  carboxy-3-hydroxy-8-methyl-azaspiracid  17 
AZA25 AZA3  -H2O 21-22-dehydro-22-desmethyl-azaspiracid  17 
AZA26 AZA1  -H2O 21-22-dehydro-azaspiracid  17 
AZA27 AZA6  -H2O 21-22-dehydro-22-desmethyl-8-methyl-azaspiracid  17 
AZA28 AZA2  -H2O 21-22-dehydro-8-methyl-azaspiracid  17 
AZA29 AZA3  COOCH3 22-desmethyl-azaspiracid-1-methyl-ester  17 
AZA30 AZA1  COOCH3 Azaspiracid-1-methyl-ester  17 
AZA31 AZA6  COOCH3 22-desmethyl-8-methyl-azaspiracid-1-methyl-ester  17 
AZA32 AZA2  COOCH3 8-methyl-azaspiracid-1-methyl-ester  17 
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2.3. Isolation of AZAs 
 
While other toxins (e.g., DTX2 or YTX) have been isolated from mussel tissue as well as 
phytoplankton, isolation of AZAs has only been carried out from mussel material. Although 
Protoperidinium crassipes has been identified as a potential producer of AZA 
31, attempts at culturing 
or bulk sampling of this dinoflagellate for the purposes of toxin analysis and isolation have not yet 
been successful (See Section 3). 
Initial isolation of AZA1 from contaminated mussel tissue consisted of extraction with acetone, 
liquid-liquid partitioning with hexane and 80 % aq. methanol, followed by chromatographic clean-up 
on silica gel, size exclusion chromatography (SEC) on Toyopearl HW-40 and ion exchange 
chromatography on two different materials (cationic exchanger CM650, anionic exchanger DEAE) 
2. 
Final purification of the toxin was achieved by further chromatography on Toyopearl HW-40. To 
isolate AZA2 – AZA5, Ofuji et al. introduced further clean-up steps 
13, 14. A second liquid-liquid 
partitioning with ethyl acetate and water helped in removing salts in addition to the hexane partitioning 
step. Low-pressure reverse phase chromatography on a C18-silica material (Develosil) resulted in a 
cleaner sample to be put forward to the ion exchange steps. This helped to prevent overloading of the 
ion exchange materials. The most crucial change of the original isolation procedure was the 
substitution of a final clean up on HW-40 by a reverse phase C18-polymeric material (ODP-50, 
Asahipak). Chromatography on this material facilitated the separation of the methyl and hydroxy-
analogs of the toxin. 
Isolation of AZA1 for production of a certified reference material (CRM) using a different 
extraction procedure was reported recently 
32.  Hepatopancreas (HP) from M. edulis were extracted 
with ethanol and partitioned with ethyl acetate and 1N NaCl solution as well as with hexane and 
90% methanol. The sample was further purified using vacuum liquid chromatography on silica, SEC 
on Sephadex LH-20, flash chromatography on LiChroPrep RP-8, and a final purification step on a C8-
silica column (high performance liquid chromatography; HPLC). Using a HPLC reverse phase 
material in the final purification step has increased purity to > 95 % as determined by NMR and liquid 
chromatograph-mass spectrometry (LC-MS) 
33.  
3. Azaspiracid Ecology  
A pre-requisite to better understanding the ecological aspects of an algal biotoxin is the 
identification of the organism(s) responsible for its production. Not only does this information allow 
researchers to focus their work on known toxigenic organisms, but what is already known about the 
ecology of the causative species adds a valuable perspective on factors that may influence the 
production and distribution of the toxic compound. As has been the case for many of the major algal 
biotoxin classes, AZAs were isolated and described originally from a secondary source, namely M. 
edulis, several years after the initial poisoning outbreak 
2. Despite the fact that four additional human 
intoxications have followed the original event in 1995 (Table 1) and AZAs have become more 
widespread (Table 3), now including multiple European countries as well as Morocco and eastern 
Canada, the identity of the toxin producer remains elusive. 
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Table 3. Azaspiracid analysis in marine shellfish and crustaceans. 
                 
Country  Region / City 
Year(s) 
observed 
Organism 
Maximum 
conc. in whole 
flesh (µg/g) 
a 
Ref. 
Ireland West  coast 
1995, 1997, 
1999, 2000, 
2001, 2005, 
2006, 2007 
Mytilus edulis, 
Crassostrea gigas, 
Ostrea edulis, 
Pecten maximus, 
Tapes philipinarum, 
Ensis siliqua, 
Cerastoderma edule
8.0 7,  33 
Norway 
SW coast / 
Sognefjord 
1998  M. edulis  0.82 
b 34,  35 
England  E coast / Craster  1998  M. edulis 0.13 
b 35 
Spain Galicia  2001  M. galloprovincialis 0.24 36 
France Brittany  2001  P. maximus 0.80 36 
Denmark   2002  M. edulis <LOQ 37 
Portugal Southern  coast  2003 
M. galloprovincialis, 
Donax spp. 
0.016 38 
Morocco NW  coast  2004 M. galloprovincialis 0.9 4 
Canada Nova  Scotia  2005 M. edulis  <LOQ 
M. Quilliam, 
pers. comm. 
Sweden Tjärno  2005  Cancer pagurus 0.019 
c 39 
Norway  North coast  2005, 2006  Cancer pagurus 0.049 
d 39 
a  Concentrations less than 0.01 µg/g are typically below the limit of quantification (LOQ) and should only be seen as 
indicative of presence. 
b  HP value. Total tissue was not available. 
c  Highest value detected in HP. No AZAs were detected in the white meat (claws + body). 
d  Values up to 0.733 µg/g were observed in the HP. 
 
There have been several attempts to identify the AZA producing organism(s) and the polyether 
structure of these compounds might suggest a dinoflagellate origin 
2, 40, as has been demonstrated for a 
number of other polyether biotoxins (e.g., BTX, ciguatoxin (CTX), DTX, YTX, PTX). Most notable is 
the effort by James et al. involving the isolation by hand and extraction of 2000 cells of the 
heterotrophic dinoflagellate,  P. crassipes 
30, 41. These authors reported the detection by liquid 
chromatography-multiple tandem mass spectrometry of AZA1, 2, and 3 in the P. crassipes extract 
(equivalent to 200 cells), leading them to propose this taxon as capable of synthesizing AZAs 
30. 
Nonetheless, while others have detected AZAs in the plankton 
32, 42, follow-up investigations involving 
the isolation of Protoperidinum spp. (including P. crassipes) cells from field samples and analysis by 
mass spectrometry have yet to corroborate these earlier findings 
43. In addition, cell counts of 
Protoperidinium spp. ranging from 600 to 900 cells L
-1 have been associated with little or no AZAs in 
Irish mussels 
44. 
The ability of P. crassipes to accumulate measureable amounts of AZAs is not in question 
30; 
however, the heterotrophic nature of this dinoflagellate (acknowledged by James et al. 2003) requires Mar. Drugs. 2008, 6  47
 
consideration of its potential role as a vector rather than progenitor of these toxins 
44. Off the 
southwestern coast of Ireland, Gribble et al. 
45 observed P. crassipes (in addition to 31 other 
Protoperidinium spp.) in abundances that could account for consumption of 30% of the standing stock 
of phototrophic dinoflagellates per day. In addition, Miles et al. 
43 observed P. crassipes and other 
Protoperidinium spp. cells ingesting Dinophysis spp. in field material, likely explaining the source and 
consistent presence of either OA or PTX in isolated cells of the former species. It is possible that the 
physiological status of the P. crassipes cells isolated by James et al. was optimal for toxin production. 
In fact, it is well-established that algal biotoxin levels associated with other known toxigenic species 
can vary from high to undetectable in field populations, likely in response to various environmental 
factors 
46. Moreover, differences in toxin production among Protoperidinium spp. might not be 
unexpected given the moderate to high degree of LSU rDNA sequence variability (i.e., base pair 
substitutions, insertions, deletions) between and within species of this genus. 
47. Although several 
investigators have maintained P. crassipes in laboratory cultures, attempts to confirm production of 
AZAs and manipulating environmental variables to determine their effects on growth and toxicity 
were not successful. Such an impediment was experienced for several decades with the OA/DTX 
producers  Dinophysis spp., until the elegant work of Park et al. 
48 revealed a complex trophic 
relationship with the kleptoplastidic ciliate Myrionecta rubra and its cryptophyte prey Teleaulax sp., 
which provided the key to survival and growth in culture of D. acuminata. Similar insights may be 
required to elucidate the appropriate culture conditions for growth of putative AZA 
producers/accumulators. It is certainly feasible that AZAs or their biosynthetic intermediates are 
synthesized by multiple species of protists or even bacteria, both of which can serve as prey for 
heterotrophic or mixotrophic taxa such as Protoperidinium and other dinoflagellates 
43, 49, 50. Indeed, 
bacteria and cyanobacteria are known producers of a diverse array of polyether compounds 
51, 52 that 
could include the structural building block(s) of AZAs. 
Although the true source of AZAs awaits confirmation, analysis of plankton samples has provided 
information on the suite of analogs potentially available to shellfish and other organisms in adjacent 
trophic compartments. In addition to the isolation and extraction of single cells outlined above, an 
approach employing mesh bags containing a synthetic resin to adsorb both particulate and dissolved 
algal biotoxins has been used to obtain samples from the water column 
53, 54. Bags/disks of exposed 
resin or resin-containing cartridges 
53 through which water has been pumped (enabling large volumes 
to be concentrated; C. Miles, pers. comm.) are then extracted and analyzed for AZA content and 
composition. To date, only AZA1, 2, and 3 have been detected in the plankton/water column and in all 
cases the toxin composition was dominated by AZA1, comprising at least 80 percent of total AZAs 
30, 
32, 42, 55. Together, these findings indicate that the remaining AZA analogs (see Table 2) isolated from 
shellfish are likely produced once the former three analogues are incorporated into the digestive tract 
and tissues of these organisms; however, the mechanism(s) by which such bioconversions occur (e.g., 
physico-chemical vs. enzymatic processes) remain to be determined. Given the recent commercial 
availability of an AZA1 CRM 
56 and the anticipated production of CRMs for AZA2 and 3, studies of 
AZA bioconversions by specific shellfish tissues or isolated enzymes are now possible and will 
provide further insight as to the natural origin of other AZA derivatives. In addition, once 
identification and/or laboratory culture of the AZA-producing organism(s) are achieved, studies can be 
conducted to further assess in vivo biotransformations, as reported for other algal biotoxins such as Mar. Drugs. 2008, 6  48
 
DSP and paralytic shellfish poisoning (PSP) toxins 
57. Such experiments should also be used to begin 
examining the potential for direct physiological effects of AZAs on species known to accumulate these 
toxins, about which little is currently known.  
Much useful information can be gained by examining the spatio-temporal relationship between 
biotoxin profiles of the toxigenic organisms and those in vectoring species (e.g., shellfish). Once the 
extent and kinetics of biotransformations are established for individual vectors following exposure to 
plankton-derived toxins, it may be possible to determine the toxin source (for no/minimal conversions) 
or potentially estimate the timing and duration of a bloom event (for more extensive toxin metabolism) 
as for the PSP toxins 
58. Azaspiracid toxin profiles have been examined in both a single algal species 
30 
and in bulk plankton material 
32, 42, with AZA1 clearly predominant in all cases and AZA2 detected in 
far lower amounts. However, while AZA3 was present in isolated cells (< 10%), it was not detected 
consistently in bulk samples, suggesting either a different toxin source organism(s), another strain(s) of 
the same species with a different intrinsic toxin composition, or an environmental modulation of toxin 
composition, none of which can be confirmed or refuted at this time. The fact that AZA3 did not occur 
in the bulk plankton sampled 
32, 42, yet was found in co-occurring mussels, suggests that this analog 
may also be produced via biotransformation in bivalves. 
From a seasonal perspective, it appears that AZA contamination of shellfish above the EU 
regulatory action limit (> 0.16 µg/g) has been detected between mid-summer and mid-winter from 
northern/western European waters 
33, 35, 59 to its present, southern-most extent in Morocco (July,   
~0.9 µg/g) 
4. In certain cases, the presence of AZAs in phytoplankton does correspond to the timing of 
shellfish contamination, yet toxin levels in bivalves can remain elevated for eight to twelve months 
following the initial exposure 
7, 55, lasting into the winter months when conditions are generally 
unfavorable for phytoplankton growth. In the case of mussels, this protracted contamination was 
suggested to result from the movement of AZAs from their initial location in the HP into other tissues, 
where depuration occurred more slowly 
7, 35, 36, 55, 59-61, but more recently, the presence of a putative 
AZA-binding protein(s) that may prolong retention time in shellfish has been studied. Specifically, a 
45 kDa protein of unknown identity has been isolated from the HP of AZA contaminated M. edulis 
that binds to AZA 
62. Alternatively, the prolonged retention of AZAs during winter months may at 
least in part be explained through reduced metabolic activity of shellfish during periods with reduced 
temperatures. However, the continued or sporadic presence of AZA-producing species as a de novo 
toxin source during this prolonged “depuration phase” can not be discounted 
33. It should also be noted 
that the DSP toxins (i.e., OA, DTXs) have been reported to co-occur with AZAs in shellfish during 
some years but not others 
32, suggesting that the organisms producing these two toxin classes may 
share certain growth requirements or seasonal distributions, but are likely distinct taxa. 
Bioconversion of algal toxins once taken up from the plankton by vector species can heavily 
influence net toxicity due to the often disparate intrinsic potencies of individual toxin derivatives. 
However, there are relatively scant comparative toxicity data available for the respective AZA analogs 
(see Section 4.2.1.). Published estimates based on mouse i.p. administration indicate that AZA2 and 3 
are slightly more potent than AZA1 
1, 14 and that AZA4 and AZA5 are less potent 
13. The range of 
bivalve species in which AZAs have been detected includes mussels (M. edulis, original 1995 
outbreak; M. galloprovincialis), oysters (Crassostrea gigas, Ostrea edulis), scallops (Pecten maximus), 
clams (Tapes philipinarum, Ensis siliqua, Donax spp.), and cockles (Cerastoderma edule) (Table 3) 
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36, 38, 59, 63. Note that AZAs have also been found recently in crustaceans such as crabs (Cancer 
pagurus) 
39.  
In all shellfish examined to date, either AZA1 or AZA2 represents the majority of total AZAs, with 
AZA3 generally at minimal levels or absent altogether 
4, 7, 33, 55, 59-61. Interestingly, the occurrence of 
AZA3 at concentrations representing > 5% of total AZAs has thus far been restricted to mussels, 
suggesting the possibility of shellfish species-specific biotransformations as have been reported for 
other biotoxins such as PSP toxins 
64. Toxin profiles of AZAs reported thus far are generally similar 
for a given shellfish type regardless of the geographic location. For example, profiles in Spanish 
mussels (M. galloprovincialis) are comparable to those found in both Irish and Norwegian mussels  
(M. edulis), as is the case for scallops (P. maximus) from both France and Ireland 
35, 36, 60. An exception 
to this trend was reported recently by Taleb et al. in their analysis of mussel (M. galloprovincialis) 
digestive glands from Morocco, which exhibited the apparent dominance of AZA2 (75-100%) instead 
of AZA1 
4. Again, it is not currently possible to ascribe this finding to either toxin metabolism within 
the shellfish (e.g., methylation of AZA1), the toxin composition of the planktonic source organism, or 
to evaluate the possible influence of extensive sample clean-up and concentration steps. In terms of 
tissue distribution of AZAs, some studies show a variable but clearly predominant localization of toxin 
in the digestive gland versus whole flesh (average, ~5-fold; range, ~2.5- to 10-fold) 
65, whereas others 
report the presence of toxin primarily in tissues other than the HP (64-100%) 
61. Dissection techniques 
of small organs such as the HP in raw mussels are difficult, and can lead to cross contamination of 
other organs, which may in turn explain some of the discrepancies found between the authors. It has 
been found in scallops that fluids containing domoic acid (DA) from the HP can “stain” (i.e., 
contaminate) other tissues very consistently even through further washing steps 
66. 
The implications of the preceding discussion relate primarily to predicting the potential risk to 
humans from consuming shellfish contaminated with AZAs. However, this group of toxins also has the 
potential to exert negative impacts within marine foodwebs. A recent study by Colman et al. 
demonstrated the teratogenic effects of AZA1 on embryos of the Japanese medaka, Oryzias latipes, a 
widely used in vitro fish model 
67. Drastic changes in the developmental process caused by AZA-1 
indicate that ingestion of this toxin by wild fish (or potentially other marine organisms) could decrease 
the survival rate of hatchlings and possibly cause adverse effects at the population level, in cases of 
widespread and appropriately timed exposure. Critical evaluation of this possibility will require 
confirmation of the toxin source organism, the factors influencing toxin production, and elucidation of 
routes of AZA trophic transfer. 
4. Toxicology of Azaspiracids 
4.1. Human toxicity 
Unlike many of the other well-described marine phycotoxins, relatively little is known about AZA. 
Similar to DSP toxins, human consumption of AZA-contaminated shellfish can result in severe acute 
symptoms that include nausea, vomiting, diarrhea, and stomach cramps. Due to the limited data 
available from many of the AZP events, nearly all information regarding AZA toxicology has been 
obtained from controlled in vitro and in vivo experiments. Many of these efforts have been directed 
towards assessing the risk of AZA consumption in contaminated shellfish and in turn, identifying the 
molecular target(s) of AZA, which is currently unknown.  Mar. Drugs. 2008, 6  50
 
4.2. In vivo toxicology 
4.2.1. Mouse bioassay and intraperitoneal injection  
During the initial AZP intoxication event in 1995 involving shellfish from Killary Harbour, Ireland, 
mussel extracts tested highly positive in the DSP rat bioassay and the DSP mouse bioassay 
68. 
However, in the absence of significant levels of OA or DTX2, and mouse symptomology atypical of 
DSP or YTX toxins 
1, 69, AZA1 was subsequently identified in these samples 
2. In mice, 
intraperitoneally (IP) injected acetone extracts of contaminated mussels caused “neurotoxin-like” 
symptoms characterized by sluggishness, respiratory difficulties, spasms, progressive paralysis, and 
death within 20-90 minutes 
1, 68, 70. The IP minimum lethal dose of partially purified AZA (i.e., KT-3) 
was 150 µg/kg 
1. IP injection of a lethal dose (>150 µg/kg) caused swelling of the stomach and liver 
concurrent with reduction in size/weight of the thymus and spleen 
71. There was vacuole formation and 
fatty acid accumulation in the hepatocytes, parenchymal cell pyknosis in the pancreas, dead 
lymphocyte debris in the thymus and spleen, and erosion and bleeding in the stomach. The 
pathological changes induced by AZA were stated to be unique from those induced by DSP, PSP and 
amnesic shellfish poisoning (ASP) toxins.  
The IP minimum lethal dose of AZA2 (8-methylazaspiracid) and AZA3 (22-demethyl-azaspiracid) 
were 110 and 140 µg/kg, respectively 
14, suggesting higher potency relative to AZA1. However, AZA4 
and AZA5 (hydroxylated versions of AZA3; see Table 2) are less potent with lethal dose values of 470 
and < 1000 µg/kg, respectively 
13. Assuming equivalent degrees of purity, the order of AZA analog 
potency by IP injection appears to be AZA2 > AZA3 > AZA1 > AZA4 > AZA5. However, future 
studies should further corroborate these findings through sufficiently replicated and controlled LD50 
(lethal dose, 50%) determinations using toxins of known purity.  
4.2.2. Acute oral administration 
Crude extracts of AZA (> 900 µg/kg) were given orally to mice via gastric intubation 
71. At six fold 
the IP injected dose that induced 100% mortality, all mice survived with no clinical signs after 24 h. 
However, mice autopsied at 4 h displayed various gastrointestinal (GI) perturbations such as 
accumulation of fluid from the ileum, and necrosis of epithelial cells on the microvilli. At 8 h these 
effects were further exacerbated, but at 24 h, with the exception of fused microvilli, were 
predominantly absent. These observations are strikingly similar to many chemically-induced models of 
inflammatory bowel disease (IBD) such as Crohn’s disease and ulcerative colitis 
72.  
Subsequent studies using purified material have further detailed the effects of AZA1 on mice 
73. 
Male ICR mice were orally administered single doses of AZA1 ranging from 300 to 900 µg/kg for up 
to 24 h. All mice receiving 900 µg AZA1/kg were sacrificed prior to 24 h. Although there was not a 
clear dose-response, likely due to insufficient experimental replicates, an approximate oral minimum 
lethal dose with purified AZA1 was 500 µg/kg. Lower doses of 300 µg/kg induced fatty acid droplet 
accumulation in the liver as soon as 1 h following intubation, followed by sporadic degeneration and 
erosion of the small intestinal microvilli, vacuole degeneration in epithelial cells, and atrophy of the 
lamina propria at 4 h. Mid-level doses of AZA1 (500 to 700 µg/kg) revealed progressive intestinal 
erosion at 8 h and continued atrophy of the lamina propria at 24 h (see Figure 3). However, at 24 h 
there were fewer degenerating epithelial cells in the microvilli suggesting some signs of recovery. By 
24 h, the liver had increased in weight by 38% in the 500 µg/kg dose group. There were time- and 
dose-dependent effects on the number of necrotic lymphocytes in the thymus, spleen, and the Peyer’s Mar. Drugs. 2008, 6  51
 
patches of the small intestine, which was elegantly supported by quantification of the number of non-
granulocytes (lymphocytes, monocytes, macrophages) in the spleen. AZA treatments of 600 and 700 
µg/kg resulted in a 33% decrease in the number of non-granulocytes, which were primarily T and B 
lymphocytes. There were no reported histological changes associated with the kidney, heart, and lung, 
and unfortunately, brain tissue was not examined. Compared to mice orally exposed to OA, the 
damage elicited by AZA was slower in onset with much longer times required for recovery 
73. Many of 
these same effects were also observed in mice treated with synthesized AZA1, but with slightly 
reduced potency (i.e., minimum lethal dose >700 µg/kg vs. ~500 µg/kg with natural AZA1) 
74. 
Unfortunately, percent purities were not reported. In addition, the diastereomer C1-C20-epi-AZA1 had 
at least a 3- to 4-fold reduction in in vivo potency (ca. > 3000 µg/kg) with virtually no morphological 
effects on the GI system, thus suggesting that stereo-specific orientation of the molecule is important 
for induction of enhanced toxicity. This finding may also corroborate some of the in vivo differences 
between the crude extracts and the purified toxin. Twelve truncated AZA1 analogs, produced during 
the total synthesis of AZA1, did not elicit any signs of toxicity suggesting that correct orientation and 
full length of the molecule are required for full potency. It is also suspected that since the effects 
elicited by AZA are not localized to only the GI system, that AZA1 and/or its metabolites can be 
absorbed from the GI system and can be at least partially distributed to various organ systems (P. Hess, 
unpubl. data). Due to limited toxin supplies, there are no data available on the potency of any 
additional AZA analogs (i.e., AZA2, 3) via oral administration. As such, future studies are necessary 
to determine the LD50 values for at least AZA1, 2, and 3.  
Figure 3. Scanning electron micrographs of mouse small intestinal villi (A) at 8 h 
following a 700 µg/kg acute oral dose of AZA1 and (B) undamaged villi for comparative 
purposes. Photos courtesy of Dr. Emiko Ito, Chiba University, Japan.  
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4.2.3. Repeated oral administration 
In another series of in vivo exposure studies, mice were orally administered repeated doses of AZA1 
and then monitored for recovery 
75. Severe injuries were induced by two repeated doses of 250, 300, 
350, or 450 µg/kg, two days apart, and recovery was monitored for up to 90 days. Of the 16 mice 
receiving 450 µg/kg, 11 died prior to the second dose, suggesting a revised minimum oral lethal dose 
of < 450 µg/kg. In fact some mice died at 250 and 300 µg/kg, but only two replicate mice were 
available for each dose. Pathological effects were similar to those reported in above during acute oral 
administrations and IBD in human and murine models. Recovery times for each tissue were: liver = 7 
days; lymphoid = 10 days; lung = 56 days, and the stomach = >12 weeks. During this time there were 
also signs of bacterial infection in the stomach lining. Although these findings of protracted recovery 
times are likely a function of tissue-specific turnover time and the rates of AZA1 metabolism and 
elimination, they correspond with the in vitro findings of the irreversible nature of AZA1 induced 
cytotoxicity 
76 (see Section 4.3). In a separate set of experiments, mice were orally administered up to 
40 repeated, low doses of AZA1 (1 to 50 µg/kg) over a period of 145 days (ca. 2 gavages per week) 
75 
. Ten percent of the mice survived the 40 repeated injections at the highest dose (50 µg/kg), as the 
other 90% were sacrificed due to extreme weakness, and 30% of the mice in the 20 µg/kg treatment 
group were also sacrificed early. Reductions in the weight of various tissues (heart, liver, kidney, 
spleen, thymus) appeared to be manifested by up to a 35% whole body weight loss. These effects were 
likely due to reduced nutrient absorption in the eroded GI tract. Similar to the effects of higher oral 
AZA1 doses (> 250 µg/kg), the GI tract displayed obvious signs of erosion (i.e., edema, shortened and 
damaged microvilli) and an accumulation of gas. As well, there were typical effects on the spleen and 
thymus. However, low dose repeated exposures of AZA1 caused mild liver inflammation with 
virtually no effects on liver fatty acid content. Lung tissue displayed signs of interstitial inflammation 
and bleeding. Although not observed in a dose-dependent manner, there was a low incidence of lung 
tumor formation (20% incidence; 4 out of 20 mice in the 20 and 50 µg/kg treatment groups) and 
hyperplasia (enlargement of the tissue due to accumulation of cells) in the stomach (60% incidence; 6 
out of 10 mice in the 20 µg/kg treatment group). Lung tumors were only observed after 2-3 months 
into the recovery phase and were S-100 reactive. S-100 proteins were originally thought to be of 
neurogenic origin but are now known to be common among many cancerous and inflamed tissues 
77. 
Brain tissue was not analyzed in these experiments. Interestingly, microarray studies using T 
lymphocytes have identified an S-100 gene as being differentially expressed following exposure to 
AZA1 
78. Repeated treatments of mice with 1 or 5 µg/kg displayed significant GI effects suggesting 
that the lowest observable adverse effect level (LOAEL) for AZA1 is on the order of 1 µg/kg in mice, 
which is comparable with the LOAELs estimated in humans of ca. 0.4 to 2 µg/kg bodyweight in the 
two risk assessments that were conducted by the Food Safety Authority of Ireland (FSAI) 
3, 79. 
4.3. In vitro toxicology 
4.3.1. Effects on protein phosphatase activity 
Due to the similarities in GI symptoms that AZAs have in common with OA and DTXs, AZAs 
were originally classified together with the DSP toxins. It was first postulated, with good reasoning, 
that the most likely mechanism of action, similar to OA, was protein phosphatase (PP) inhibition 
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PPs are well described regulators of cell signaling pathways where they act in a manner opposite to 
that of kinases by removing phosphate groups from proteins. The serine/threonine PPs are known to be 
inhibited by OA 
81. The effects of crude blue mussel extracts containing AZAs demonstrated no 
indication of PP1 enzyme inhibition 
82 and a subsequent study utilizing the same assay format but with 
PP2A, also found no effects of purified AZA1 on enzyme activity 
83. However, we cannot exclude the 
possibility that AZA may still inhibit one of the many other types of serine/threonine PPs (i.e., PP2B, 
PP2C, PP4, PP5) or another PP sub-type (i.e., tyrosine-specific phosphatase, lipid phosphatase). In 
fact, OA and genistein (a tyrosine kinase inhibitor) have been shown to modulate the cytosolic calcium 
response induced by AZA1 in human lymphocytes 
84. 
4.3.2. Cytotoxicity 
On their own, many phycotoxins (i.e., CTX, BTX, saxitoxin) are not known for inducing cell death. 
The original observation that AZAs can cause cytotoxicity were performed by Flanagan et al. 
69, 80, 82 
using HepG2 hepatoblastoma cells and human bladder carcinoma cells (ECV-304) exposed to crude 
mussel extracts. Additional studies have since confirmed these findings, in a time- and concentration-
dependent manner, for a variety of other cell types from various mammalian sources (Table 4).  
The only cell type that has been tested so far that is not sensitive to AZA1-induced cytotoxicity 
appears to be the human colon Caco-2 cells. This is in contrast to the effects of AZA1 on intestinal 
epithelial cells in vivo as observed following oral intubation in mice (see Section 4.2.). Caco-2 cells are 
often used as a model for studying intestinal drug transport 
89 and/or transepithelial electrical resistance 
(TEER) 
90. However, these assays require a standard 17 to 21 day growth period to allow for cell 
growth, monolayer formation, and cellular differentiation. It is unclear if the Caco-2 cells listed in 
Table 4 were allowed to grow to these densities prior to the addition of AZA1, and if so, what effect 
this might have on observation of a cytotoxic response. At high cell densities, the viability detection 
substrate (i.e., Alamar blue, MTT) used in some cytotoxicity determinations will become limited. 
Nonetheless, monolayers of Caco-2 cells exposed to AZA1 have shown significant reductions in 
TEER assays when exposed to low concentrations of AZA1 (i.e., 5 nM) 
31, 86. Visual confirmation has 
demonstrated monolayer perturbations that result in a loss of electrical resistance across the epithelial 
cells suggesting that even if the Caco-2 cells are not susceptible to an AZA1-induced cytotoxic 
response, they are sensitive to the effects of AZA1 on monolayer integrity. These observations are 
more in line with the in vivo observations of Ito et al. 
73-75 (see Section 4.2.).  
During the cytotoxicity experiments listed in Table 4, a variety of morphological effects were 
observed. In T lymphocytes, cells initially responded to AZA1 by a reduction in membrane integrity, 
organelle protrusion concurrent with flattening of cells, and a retraction of their pseudopodia or 
lamellipodia 
83. This was followed by protracted cell lysis. Although caspase-3 was not induced during 
these exposures (M. Twiner, unpubl. observ.), this alone does not rule out apoptotic cytotoxicity. 
During these experiments, filamentous actin (i.e., F actin) was also monitored and observed to closely 
follow the retraction of the pseudopodia. Although actin levels were not quantified, it appeared as 
though F actin was reorganized following AZA1 exposure. Isolated enzyme assays investigating rates 
of F actin polymerization and depolymerization suggest no direct effect of AZA1 on this protein (M. 
Twiner, unpubl. observ.). Experiments using human breast cancer cells and mouse fibroblasts exposed 
to AZA1 also illustrate reductions in cellular proliferation and density that are similar to the action 
elicited by YTX 
85. However, F-actin measurements indicated no change following 1 nM AZA1 
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Table 4. Overview of azaspiracid cytotoxicity. 
                    
Cell type  Cell line  Source  Cytotoxic 
EC50 
(nM)
 a 
Method of analysis 
b Ref. 
B lymphocyte  Raji  human  yes  1.6 *  MTT  83 
breast cancer  MCF-7  human  yes  > 1 * 
DNA content; cell 
number 
85 
Colon adrenocarcinoma  Caco-2  human  no  nd  DNA content  85 
Colon adrenocarcinoma  Caco-2  human  no  nd  Alamar blue  31, 86 
Embryonic kidney  HEK-293  human  yes  4.6 *  MTT  83 
Hepatoblastoma  HepG2  human  yes  unknown  MTT  69, 80, 82 
Lung epithelial  A547  human  yes  1.5 *  MTT  83 
Monocyte THP-1  human  yes  2.4  *  MTT  83 
Neuroblastoma 
BE(2)-
M17 
human  yes n.d. morphological  76 
T lymphocyte 
Jurkat   
E6-1 
human yes  1.1  G6PH  78 
T lymphocyte 
Jurkat   
E6-1 
human yes  3.5  MTT  83 
Bladder carcinoma  ECV-304  human  yes  unknown  MTT  69, 80, 82 
cerebellar granule cells  primary  mouse  yes  0.87  MTT  87 
cerebellar granule cells  primary  mouse  yes  n.d.  LDH  87 
Neuroblastoma Neuro-2A  mouse  yes 2.3  *  MTT  83 
Skin fibroblasts  primary  mouse  yes  > 10  DNA content  85 
Spinal cord neurons  primary  mouse  yes  n.d.  Action potentials  88 
Pituitary epithelial  GH4C1 rat  yes  16.8  MTT  83 
a  Effective concentration that results in 50% cell death at 24 h. Values designated with an asterisk (*) are EC50 values at 
48 h. Note: nd = values not determined and “unknown” indicates cytotoxicity induced by crude mussel extracts.  
b  MTT, MTS, and Alamar blue are mitochondrial enzyme-dependent viability assays. G6PH (glucose-6-phosphate 
dehydrogenase) and LDH (lactose dehydrogenase) assays are based on the release of these cytosolic enzymes from 
intact cells.  
 
AZA1 and an enantiomer of AZA1 induced distinguishable morphological and cytoskeletal (i.e., F 
actin) effects on human neuroblastoma cells following 24 – 48 h exposures 
76, 91. Low concentrations 
of AZA1 (10 nM) appear to induce retraction of the neurites (cellular projections) and cell rounding 
with simultaneous actin cytoskeleton disarrangement. Although previous studies by these authors have 
shown quantitatively decreased levels of F actin following AZA1 exposure, the concentrations of 
AZA1 required to induce these effects were very high (~7.5 µM) 
84. Interestingly, the effects of AZA1 
on morphological, cytoskeletal, and cell viability appear to be irreversible 
76, 88, 91, which may explain 
the protracted in vivo rate of GI recovery following mouse intubations (see Section 4.2.).  
DSP toxins such OA are well-described inducers of apoptosis 
92. Initial studies suggested that 
AZA1 does not induce an apoptotic response, but rather induces necrotic lysis. These observations 
were made based on cytotoxic morphological observations 
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potential changes in neuroblastoma cells 
84, and the absence of caspase-3 induction in T lymphocytes 
(M. Twiner, unpubl. observ.). However, more recent evidence suggests that AZA1 induces apoptosis. 
This is not surprising as none of the previously observed characteristics are definitive indicators of 
apoptosis. In the same neuroblastoma cells used previously to monitor the effects of AZA1 on 
mitochondrial membrane potential, caspases were subsequently shown to be activated as determined 
using caspase-specific fluorescently tagged peptides 
91. However, these data do not lend insight into 
which caspase subtype(s) (i.e., caspase-1, -3, -7, -9, etc.) is/are up regulated as the peptide sequence 
used in these experiments binds a broad-spectrum of caspases. These data of caspase activation are 
further supported by a recent in vivo study in mice where dead or dying lymphocyte cells in the spleen 
and thymus were observed to be undergoing pyknosis - chromatin condensation indicative of apoptosis 
74. Clearly, more efforts are needed to define the effects of AZAs on the apoptotic pathway.  
4.3.3. Intracellular signaling molecules 
Many AZA analogs have been shown to cause a variety of effects on intracellular signaling 
molecules. In mammalian cells, cytosolic calcium is an important secondary messenger for a variety of 
pathways, including cell death 
93, 94 and many marine toxins are known to modulate cytosolic calcium 
95-99. Human lymphocytes exposed to AZA1 (200 nM) were shown to elevate cytosolic calcium levels 
by ca. 50% above basal 
84. This response was shown to be sensitive to extracellular calcium, PKC 
(protein kinase C) activation, PP inhibition, and cAMP (cyclic adenosine monophosphate) elevation. 
In addition, elevations in cAMP were sensitive to adenylate cyclase inhibition but insensitive to PP 
inhibition and extracellular calcium. cAMP is a second messenger that responds to membrane receptor 
activation and often functions to activate kinases. Similarly, AZA2 and AZA3 also elevated cytosolic 
calcium and cAMP 
100, whereas AZA4 did not affect basal cytosolic calcium levels but did have an 
inhibitory effect on calcium uptake from the extracellular medium 
101. Differences in the effects of the 
various AZA analogs may be a function of solubility and/or purity as it would be highly unusual for a 
class of structurally related compounds (with only single methyl and/or hydroxyl substitutions) to elicit 
completely different mechanisms of action rather than, more commonly, various degrees of affinity 
and efficacy. Although these studies were unable to identify a specific mechanism of action, the 
modulation of cytosolic calcium and cAMP may be influenced by modulation of a membrane protein. 
4.3.4. Membrane proteins 
In addition to the growing body of literature on the effects of AZAs on cellular actin cytoskeleton 
and intracellular signaling pathways, there are many new and novel insights being generated by 
investigations into the effects of AZAs on membrane proteins such as claudins and cadherins. Claudins 
are integral membrane proteins involved in tight junction cell adhesion and are pivotal in paracellular 
transport of epithelial and endothelial cells 
102 with at least 24 known claudin types 
103. Caco-2 
epithelial cells exposed to AZA1 demonstrated an increase in soluble and insoluble fractions of 
claudin-2 protein expression and a decrease in insoluble claudin-3 
31. These responses appeared to be 
reversibly mediated by ERK 1,2, members of the mitogen activated protein kinase (MAPK) family of 
proteins that commonly respond to extracellular stressors or signals 
104. Epithelial-cadherins, or E-
cadherins, are transmembrane Adherens proteins that are involved in cell-to-cell adhesion 
103.  
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following exposure to AZA1 
85. And recently, it was shown that T lymphocytes exposed to AZA1 up 
regulated gene expression and protein levels of low density lipoprotein receptor (LDLR) by as much as 
3.5- and 2.5-fold, respectively 
78. This LDLR effect appears to be in response to decreased levels of 
intracellular cholesterol caused by AZA1. LDLR is a well described membrane protein that 
endocytoses cholesterol bound to low density lipoproteins into the cell. Cholesterol is required to 
maintain membrane integrity and function and is intricately involved with tight junction and Adherens 
proteins 
105. Although premature to determine decisively, yet consistent with currently available in 
vitro data, AZA1 appears to be targeting a membrane protein such as a claudin, cadherin, or LDLR, in 
turn eliciting an effect on intracellular signaling molecules and the cytoskeleton, ultimately resulting in 
cytotoxicity. These cellular effects are also in line with the in vivo pathologies and potential 
carcinogenicity or tumor promoting capabilities of this toxin.  
5. Human health issues 
5.1. Acute illness 
As mentioned in the Toxicology sections, all symptoms observed in humans following consumption 
of shellfish contaminated with AZAs appear within hours of ingestion, and include nausea, vomiting, 
severe diarrhea and stomach cramps 
68. The illness persists for 2-3 days and full recovery has been 
established in all cases during the incident in Arranmore Island, 1997 
3. To date, no long term effects 
or illness have been reported. 
AZP remains a rare illness, as only 5 intoxication events have been reported to date (Table 1). Due 
to the similarity with ‘food poisoning’ or DSP, it has to be assumed that more cases exist; however, it 
is likely that there is a high percentage of under-reporting due to the symptoms of the illness 
disappearing rapidly (i.e., days) and no precedence for fatality. 
5.2. Risk of chronic effects 
Given that shellfish production sites remain open for production if AZA contamination levels are 
below the EU regulatory limit (160 μg/kg shellfish meat), a large number of shellfish consignments 
with low levels of AZAs have been produced in Ireland since 2001, and subsequently marketed and 
consumed in Europe.  
Some chronic illnesses are caused by chemicals that are retained in the human body for a long time. 
A prime example for such a chronic condition is cancer, which may be caused through the 
accumulation of carcinogens that may be absorbed with fatty foods, transferred to the human body 
through the blood stream and accumulate in all fatty tissues of the body. Therefore, by analogy, in 
order to evaluate whether AZAs have a potential for causing chronic effects, it is important to know 
whether AZAs, or their metabolic products, are distributed to the body via the blood stream, or 
whether they are simply excreted with food after exerting their toxic action in the intestine. Although 
pilot studies with mice have shown increased occurrence of cancer and hyperplasia with a protracted 
rate of recovery in the test animals exposed to AZA1 
75, this increase in cancer was not observed in a 
dose-dependent manner (1 case at highest dose of 50 µg/kg body weight, 3 cases at the intermediate 
dose of 20 µg/kg
 body weight). Also, the number of mice used in this study was relatively low (due to 
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studies to elucidate the carcinogenic potential of AZAs. In addition, other toxic effects were observed 
in mice exposed to AZA over 20 weeks 
75, particularly in the highest exposure dose, therefore, chronic 
effects cannot be excluded at this stage. Damage caused by AZA to epithelial cells of the intestinal 
tract in vivo 
73-75, were supported in vitro by Hess et al. 
106, providing a model to explain the diarrhetic 
symptoms in humans. It is conceivable that AZAs may contribute to chronic disorders in the GI tract, 
such as IBD (i.e., Crohn’s disease, ulcerative colitis), or cancers of the stomach, intestines and colon. 
However, it remains to be established whether the suspected bioavailability and toxicity of AZAs are 
similar when dosed as part of naturally contaminated shellfish as food.  
To date, due to the scarcity of epidemiological data, it has not been possible to establish any link 
between AZAs and the occurrence of cancer or birth defects in humans. Any studies presuming 
consumption of AZA-contaminated shellfish and statistically comparing a hypothetically increased 
occurrence of chronic disease with levels of AZA in shellfish would be convoluted by the multitude of 
potential carcinogenic agents and contaminants of any consumer area. Therefore, it is the opinion of 
the authors that research in this area should focus on the toxicokinetics (i.e., absorption, metabolism, 
distribution, and elimination) of AZAs in animals to establish the possible fate of AZAs in the human 
body, until larger amounts of synthesized AZA or AZA-contaminated shellfish are available 
facilitating statistically valid long-term exposure trials. Also, when the mode of action is clarified from 
in vitro studies, further studies may be necessary to evaluate chronic effects, depending on the 
mechanism elucidated. 
5.3. Possible synergistic effects of AZAs with other shellfish toxins 
A number of different toxin groups may co-occur in shellfish, and thus the question arises as to 
whether these toxins would interact with each other to suppress or enhance their respective toxicities, 
or whether the different toxic effects are simply independent of each other. No observations have been 
reported in humans to date on any synergistic effects of different phycotoxin groups. This area of 
investigation is a relatively new direction in toxicology. While guidelines have been discussed since 
1999 
107, the UK Food Standards Agency (FSA) has published a draft action plan on risk assessment of 
mixtures of pesticides and similar substances 
108. Similarly, the US EPA has issued a document on a 
strategy for risk assessment of the cumulative effects of co-occurring pesticides 
109; however, no such 
risk assessments are currently available for shellfish toxins. 
While co-occurrence of the OA-group and PTXs are essentially pre-programmed due to production 
of both groups by Dinophysis spp., the co-occurrence of other toxins is determined by overlapping 
autecology and toxigenic potential of their algal producers. As quantitative data on the occurrence of 
AZAs in shellfish has been mostly reported from Ireland and Norway, the information on possible 
combinations is very limited. In Ireland, several co-occurrences of AZAs with toxins from the OA-
group have been observed during 2001, 2005, 2006 and 2007 (Marine Institute, unpubl. monitoring 
data). On one occasion, the appearance of AZAs and OA/DTX2 in mussels (M. edulis) was 
simultaneous in mid-August 2001 at Bantry Bay, Southwest Ireland 
33, and depuration of both toxin 
groups followed a similar rate. Subsequent analysis of these shellfish also showed that PTXs had been 
present in these shellfish at the same time 
20. Therefore, it must be assumed that co-occurrence of at 
least these 3 toxin groups is possible. In Norway, the co-occurrence of AZAs with YTXs may be a Mar. Drugs. 2008, 6  58
 
problem, as both toxin groups have been observed in this region, in addition to analogs of SPX, PTX 
and OA 
110. 
Since AZAs and OA-group toxins both initially target the GI tract leading to acute GI disorders, 
possible interactions of these toxin groups are of obvious concern. Although the effects of AZA and 
OA in the intestine of mice are unique, both at molecular and at microscopic levels, both toxins appear 
to target the microvilli 
73-75. OA transiently caused shortened microvilli, whereas AZA caused distinct 
and protracted microvilli erosion. By analogy, both toxins separately cause diarrhea in humans after 
consumption of contaminated shellfish. Therefore, it seems very likely that the effects of combined 
AZAs and OA-group toxins would at least be additive, if not synergistic. However, to date, no 
information is available from human epidemiology, and no animal experiments have been conducted 
in this area. 
Synergistic toxicity of AZAs and YTXs is a further concern. With the exception of some effects on 
mouse cardiac muscle cells 
111, YTXs have not been explicitly involved in human poisoning and have 
not shown any toxicity when orally administered to mice 
112, 113. Nonetheless, their toxic potential is 
still significant as estimated from IP injection in mice (LD50 = 100-700 μg/kg bodyweight) 
113, 114. 
Therefore, it could be postulated that the toxicity of YTXs may be of greater importance to human 
health if they co-occur with AZAs. During such co-occurrence, AZAs could affect the permeability of 
the intestinal barrier through an eroded epithelial or GI lining, and YTXs may be able to enter the 
human blood stream and subsequently cause damage that they otherwise could not exert. 
 
5.4. Safe levels of AZAs in shellfish and allowable daily intake 
 
Considering the lack of knowledge on the long term exposure potential of AZAs with the fact that 
all other shellfish toxins have only been evaluated for their acute toxic potential, experts consulted 
during the ad hoc consultation by FAO/IOC/WHO 
115 advised regulators to consider only known acute 
effects in humans when establishing safe levels of AZAs in shellfish. Allowable daily intakes require 
the evaluation of repeated intake and a risk from long term exposure. As long term effects have not 
been shown to date in humans, the establishment of allowable daily intakes is not appropriate. 
Therefore, a proposed regulatory level of AZAs in shellfish has only been obtained through estimation 
of the consumption of a single portion of shellfish and through the estimation of an Acute Reference 
Dose (ARfD). 
Analogous to other formal risk assessments, the risk assessment by FSAI also used epidemiology 
data to establish the ARfD 
3. This risk assessment was based on a statistical approach, which makes 
use of known distributions of all components involved in a poisoning event (i.e., mussel weight, 
portion size consumed, concentration of AZAs in mussels, etc.), and the result is a distribution of most 
likely ARfDs. It is then the responsibility of risk managers and regulators to adapt an ARfD from this 
distribution (e.g., the most probable value or the ARfD covering with 95% probability all possible 
ARfDs). The selected ARfD is then used, in combination with an appropriate safety factor, to derive a 
No Observable Adverse Effect Level (NOAEL). This statistical approach used for risk assessment of 
AZAs is novel and has not been used by the FAO/IOC/WHO expert group; however, as cited in the 
risk evaluation by FSAI, “it is the opinion of expert toxicologists that a more accurate estimate may be 
obtained using this method” 
115.  Mar. Drugs. 2008, 6  59
 
The FSAI 2006 risk assessment was the second risk assessment by this group, following the first 
one in 2001 
79. The reason for review of the earlier risk assessment was the availability of new 
scientific data allowing a re-estimation of the amount of toxin consumed by the people who fell ill 
during the 1997 Arranmore AZP incident (Table 1), which is still the best documented incident to date. 
The new evidence mostly related to new information on the tissue distribution of AZAs in mussels (M. 
edulis), the effects of heat-treating mussels on their toxin content and the ratios of AZA analogs 
observed in shellfish tissues 
65. The median, or most likely ARfD derived in this assessment was 
0.63 μg/kg body weight, while the most likely LOAEL was divided by a safety factor of 3. When 
assuming consumption of a 250 g portion of shellfish flesh and a human average weight of 60 kg, this 
ARfD translates into a proposed regulatory level of AZAs in shellfish flesh equal to 160  μg/kg.  
Co-incidentally, this is the same level as was transposed into EU legislation in 2004 (853/2004/EC) 
116. 
This limit of 160 μg AZA/kg shellfish in flesh has also been proposed by the EU Commission for 
Health and Consumer Protection (EU-DG Sanco) to Codex Alimentarius as part of a draft Codex 
standard on fish and fisheries products during recent meetings of Codex 
117, 118. As this limit had also 
been implemented in EU legislation since 2002 (2002/225/EC) 
119, although now superseded by 
853/2004/EC 
116, it had been implemented in Ireland since 2002. Surveillance information from the 
Marine Institute, the Irish National Reference Laboratory (NRL) as cited in Anon. (2006) 
3, suggests 
that numerous lots of shellfish have been produced since 2002 that were contaminated at levels close 
to this concentration. Although there is a high likelihood of under-reporting of illnesses due to the 
rapid recovery, it has been estimated by the authors that millions of portions of shellfish (several 
thousand tons) with low but significant AZA-levels have been consumed since 2001 (contamination 
range of 100 – 160 µg/kg). Therefore, assuming a reporting rate of only 0.1 %, there should have been 
thousands of reports of illness if the current limit of 160 µg/kg was unsafe. However, not a single 
report was received on any poisoning incident from these shellfish, over the period from 2001 to 2007. 
Therefore, it can be assumed that existing risk management practise has shown - in retrospect - that 
this level is indeed a safe level protecting consumers from acute effects of AZAs in shellfish. 
It should be noted that this limit has been derived from epidemiological observations caused by a 
mixture of naturally occurring analogs. As outlined in the section on Chemistry of AZAs, it is clear 
that at least 28 analogs may occur in shellfish. The limit has been derived from consideration of the 
three main analogs only (AZA1, 2 and 3). As shown by Satake et al. 
2, and Ofuji et al. 
13, 14, AZA4 and 
5 have a lower toxicity in mice when injected via IP, suggesting a decreased toxic potential for 
oxidized AZA analogs, a very common structure-activity relationship. All other analogs 
15-17 occur at 
very low concentrations and are even further oxidised, suggesting that their toxic potential is reduced 
from both the structure-activity relationship established by Satake et al. and Ofuji et al. and from their 
concentration. Additionally, no information was available from the 1997 Arranmore AZP incident on 
these analogs, and therefore, their consideration would have been very difficult.  
5.5. Regulatory limits in the EU and implementation approaches 
The first regulatory limit established explicitly for AZAs was 100 μg/kg shellfish meat, and was 
introduced in Ireland in 2001 as a consequence of the risk assessment by Anderson et al. 
79. However, 
this limit was only introduced as a working practice in the management of Irish shellfish production, 
and was seriously flawed by the lack of tools available for implementation of this limit. Although the Mar. Drugs. 2008, 6  60
 
mouse bioassay for lipophilic toxins 
21 had never been officially validated for detection of any shellfish 
toxin, it was clear from studies by Satake et al. 
2 and Ofuji et al. 
120 that the test was not likely to detect 
AZAs at this level, therefore ruling out use of the reference test prescribed by European legislation at 
the time 
121. Only one other method was available during this period (i.e., LC-MS); however, this 
method had also not been officially validated and, as no AZA standards were internationally available, 
validation efforts were severely hampered. 
The EU Commission for Consumer Health and Protection (DG Sanco) held a workshop in Brussels 
in 2001 and reviewed available information 
122, leading to the introduction of a provisional limit for 
AZAs of 160 μg/kg shellfish meat 
119. Although, the risk evaluators initially proposed a safe limit of 
80 µg/kg, it was believed at the time that the reference test (MBA) would be able to only implement a 
level of 160 µg/kg. More recent considerations suggest that the MBA for lipophilic toxins only has, at 
best, a 50% chance of detecting toxins at this level and is not appropriate to effectively manage 
shellfish production. Nevertheless, the regulatory limit was based on the LD50 of the MBA, 
demonstrating that food safety regulations can only be as effective as the methods available at the 
time. This unsatisfactory situation had generated significant discussion in the working groups of the 
EU NRLs and the Community Reference Laboratory (CRL). In an initial attempt to improve the 
situation, the EU Commission responded through a call for research projects on the validation of 
alternative (i.e., non-animal based) methods for all lipophilic toxins problematic in the EU, including 
OA/DTXs, PTXs, YTXs, and AZAs. In late 2004, the EU funded three projects in this area, BIOTOX 
(www.biotox.org), BIOTOXmarin (www.biotoxmarin.de) and DETECTOX (www.detectox.eu), all 
due to finish in 2007. In the meantime, the expert consultation by FAO/IOC/WHO 
115 has 
recommended the official validation of LC-MS as a reference test for many lipophilic toxins, including 
AZAs. Additionally, it is a legal obligation for the EU CRL to lead the NRLs in method development 
and validation 
123. Thus, in 2005, DG Sanco has also explicitly tasked the EU-CRL to collaborate with 
the NRLs on the validation of LC-MS methods as alternative tools to replace the current MBA 
reference test. Furthermore, a workshop between DG Sanco and the European Centre for the 
Validation of Alternative Methods (ECVAM) recommended reducing and replacing the MBA for 
lipophilic toxins as rapidly as possible due to its technical limitations and ethical concerns 
124. In 
anticipation of a positive outcome of these efforts, DG Sanco has also transposed these regulations into 
a more recent updated version of European Food Safety Legislation 
116, 125, 126.  
Recent progress and difficulties in the preparation of adequate quality control tools in the 
development, validation and implementation of analytical methods for shellfish toxins has been 
reviewed by Hess et al. 
26. Previous work by the authors in collaboration with the National Research 
Council-Canada (NRC-Canada) has led to the production of a CRM for AZA1 that is now 
commercially available worldwide 
31, 56. The same project (Azaspiracid Standards and Toxicology; 
ASTOX), funded under the Irish National Development Plan 2000-2006, also led to significantly 
improved understanding on the preparation of homogenous and stable reference shellfish tissues for 
lipophilic toxins, including AZAs 
27, 127, 128; some of these materials have also been used in proficiency 
testing via a scheme for Quality Assurance in Marine Environmental Matrices in Europe 
(QUASIMEME, 2006-2007). Finally, the ASTOX project, in collaboration with the NRCC and the 
Institute for Reference Materials and Measurement (IRMM), has also yielded two candidate certified 
reference shellfish tissues, one mussel material contaminated predominantly with AZAs, the other one Mar. Drugs. 2008, 6  61
 
a mussel material contaminated with a number of toxins groups, including OA/DTXs, AZAs, YTX, 
PTX2, SPX and others. Therefore, significant progress has been made in the preparation of QC tools 
for the quantitative determination of AZAs in shellfish tissues. Further work in this area should include 
the certification of the candidate reference tissues and the preparation of reference standards for AZA2 
and 3, two analogs that appear also of toxicological importance and that have been explicitly regulated 
in the EU 
129. 
6. Conclusions and future directions 
In less than a decade since the identification of AZA1 in Irish shellfish, much progress has been 
made in the field of AZA research and its application to protecting the health of seafood consumers. 
Most convincing is the fact that although there were five AZP events between 1995 and 2000, since 
that time (over 7 years) there have not been any further AZP events due to accidental ingestion; a 
testament to the regulatory mechanisms in place and not for lack of AZA in shellfish over this period. 
This is clearly a case of where advances in research knowledge have aided various shellfish 
monitoring programs, contributed to the implementation of safe regulatory limits, and ensured 
compliance by the aquaculture industry. Nonetheless, AZA research remains in its infancy. Major 
research efforts are required to identify the causative organism(s), which will subsequently be useful in 
determining the environmental and genetic cues that influence or trigger the production of AZAs. 
Monitoring programs will also benefit as there is often, but not always, a correlation between the 
presence of potentially toxigenic phytoplankton species and the subsequent accumulation of toxins in 
shellfish. The impacts of AZAs on shellfish fecundity and viability are only anecdotal and require well 
controlled in vitro and mesocosm studies for these effects to be determined. With the exception of 
AZA accumulation in various species of shellfish, routes of trophic transfer through the food web are 
completely unknown, although AZAs have recently been found in crustaceans. AZA could have 
serious impacts on the fishery industry as the teratogenic effects of AZA1 have been documented in 
fish embryos.  
Until recently, LC-MS methodologies for the detection of AZAs were hindered by the lack of an 
AZA CRM. Although AZA1 is currently available through the NRC-Canada, there is no commercial 
source for some of the other important, and potentially more toxic, AZA analogs (i.e., AZA2 and 3). 
Other detection methods such as an ELISA (enzyme-linked immunosorbent assay) have recently been 
developed for AZA 
130 but are not yet commercially available. Relative to LC-MS detection, ELISAs 
are economical, high-throughput, often have very low detection limits, and require less training to 
operate, making them very suitable for many end users such as researchers and aquaculture managers. 
A supply of a readily available AZA ELISAs would allow for major advancements in the field of AZA 
research.  
Much progress has been made in the areas of AZA toxicology and associated human health issues, 
but similar to the other areas of AZA research, efforts are impeded by the lack of purified toxin 
standards and high-throughput detection methods. AZA1 administered to mice via IP injection and oral 
intubation is highly toxic with similar lethal doses. Analogous to DTX1 
114, the in vivo potencies of 
AZA do not appear to be related to the route of administration. These findings are in contrast to 
microcystin-LR 
131, palytoxin 
132, and YTX 
114 whose oral potencies in mice are at least 1-2 orders of 
magnitude lower than IP injection.  Mar. Drugs. 2008, 6  62
 
Definitive mechanism of action studies are still necessary and currently nothing is known regarding 
mixture toxicities, either with other AZA analogs or other toxin classes (i.e., OA, DTXs, DA, PTX, 
saxitoxin), that can also be found in shellfish in many of the same regions where AZAs occur. There is 
a lack of information regarding AZA toxicokinetics (i.e., absorption, distribution, metabolism, 
elimination), well characterized epidemiology studies, and detailed information on the carcinogenic or 
tumor promoting potential of AZAs. Given that azaspriacids are now being reported from the coastal 
waters of an increasing number of countries on a global scale, it is clearly imperative to advance our 
understanding of AZA toxicity and ability to rapidly detect these toxins and their progenitor(s) 
organisms. Addressing these and other issues outlined above will be among the aims of researchers, 
regulators, and public health officials over the years ahead. 
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